Abstract The molecular identification and characterization of antigenic epitopes recognized by T cells on human cancers has rapidly evolved since the cloning in 1991of MAGEA1, the first gene reported to encode a CTL-defined human tumor antigen. In the expanding field of human tumor immunology, unique tumor antigens constitute a growing class of T cell^defined epitopes that exhibit strong immunogenicity. Some of these antigens, which often derive from mutation of genes that have relevant biological functions, are less susceptible to immunoselection and may be retained even in advanced tumors. Immunogenicity and constitutive expression of the unique tumor antigens provide a strong rationale for the design of novel, patient-tailored therapies that target such determinants. Here we discuss the immunologic relevance of unique tumor antigens in the light of the prospects for exploiting such epitopes as targets for patient-specific immune intervention strategies.
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Tumor-specific transplantation antigens, leading to complete T cell -mediated elimination of a transplanted cancer by the syngeneic host, have been described on rodent chemical or UVinduced fibrosarcomas more than 40 years ago (1 -4) . The specificity of the immune response documented in vivo and in vitro against independently induced tumors led to the concept that the tumor-specific transplantation antigens were unique (i.e., expressed only by a syngeneic tumor but not by other tumors even when promoted by the same carcinogen and in the same mouse; refs. 1 -4) . After the identification of tumor-specific transplantation antigens, the search for the molecular basis of unique tumor antigens defined by T cells has been a major area of investigation for the understanding of the immune response to neoplastic cells. In 1995, the identification of a single amino acid substitution in cellular proteins (5, 6) provided evidence for the origin of this class of determinants from somatically mutated genes. These initial results confirmed earlier evidence on the mechanism that generated tumor-specific antigens after mutagen treatment of preexisting tumors (7). Somatic mutation was soon verified in human tumors as one of the mechanisms for generation of antigens recognized by T lymphocytes only on the autologous and not on HLA-matched tumors (8). This provided the evidence for the role of the immune system in surveillance of genome integrity. In the first study by Coulie et al. (8) describing the molecular basis of unique tumor antigens on a human tumor, CD8 + T cells from a patient with metastatic melanoma were shown to recognize, in the context of the HLA class I allele HLA-A2, a nine-amino-acid-long peptide, which included a point mutation occurring in one intron of the melanoma associated (mutated) antigen -1 (MUM1) gene. This study, along with the previous work on the cloning of the first gene coding for a shared human tumor antigen (MAGEA1; ref. 9), also provided direct evidence for the power of the cDNA expression library as an effective strategy to identify genes encoding tumor antigens recognized by HLA-restricted T cells.
Over the past 15 years, a large variety of tumor associatedantigens has been identified. A number of these determinants were shown to be unique antigens encoded by somatically altered, and mainly point-mutated, genes (Table 1; refs. 8, 10 -37) . The investigation on the molecular nature of epitopes recognized by antitumor T cells (see ref. 38 for a listing of human tumor antigens recognized by T cells) has not only shed light on the genetic mechanisms that generate unique tumor antigens but has also allowed investigators to identify genes that, when altered, play a relevant role in tumor biology. In fact, unique antigens recognized by patient's CD8 + or CD4 + T cells have been shown to be encoded by genes that regulate several cellular processes such as cell cycle (11, 19, 20, 26) , adhesion and motility (10, 21, 23, 30) , apoptosis (28) , stress response (16, 17, 36) , RNA processing (20, 22) , transcriptional activation and silencing (20, 32) , and general metabolic pathways (refs. 13, 14, 19, 25, 29, 31; Table 1 ). Interestingly, in several instances, the genetic alterations that yield immunogenic T-cell epitopes are also responsible for inducing Table 1 ). For these reasons, the investigation on the molecular basis of unique tumor antigens can be placed at the crossroads of cancer genetics, tumor biology, and tumor immunology. Definition of unique tumor antigens. Table 1 lists the somatically altered and mainly point-mutated epitopes recognized by T lymphocytes from peripheral blood or tumor site of cancer patients that are ''strictly'' unique (i.e., only expressed in the neoplastic cells from a single tumor). By this strict definition, unique tumor antigens include also the idiotypic determinants of the rearranged immunoglobulin of B-cell malignancies (39) . It is to be pointed out that such classification of unique tumor antigens is not straightforward as it seems. In fact, in few instances, the ''uniqueness'' of the tumor antigen is dictated by the HLA constraint on T-cell recognition, rather than by the presence of the altered gene only in one tumor. For example, identical mutations in CDK4 and b-catenin genes (Table 1 ) have been described in more than a single melanoma. However, such mutations will not lead to the generation of the antigenic determinant in patients that do not express the required HLA restricting element for presentation of the relevant epitope. Furthermore, gene alterations like mutations occurring in oncogenes or tumor suppressor genes, or chromosomal translocations encoding novel fusion proteins, can yield additional classes of tumor-specific epitopes (40 -49) . These determinants cannot be classified as ''unique tumor antigens'' because the mutations are frequently shared by several tumors (representative examples are listed in Table 2 ). These tumor-specific, mutant epitopes include the shared antigens resulting from mutations in KRAS, NRAS, and BRAF oncogenes or generated by mutations in p53 tumor suppressor gene (40 -42, 50) . The available evidence indicates immunogenicity, in vivo, of at least some of these determinants. This has been documented not only by the presence of antigen-specific T cells in patients but even by the results obtained in clinical trials of immunotherapy targeting such antigens. In fact, recently, significantly longer survival has been described in cancer patients with positive versus negative CTL responses after immunization against mutant p53 and mutant KRAS peptides (50) . Epitopes generated by chromosomal translocations include those derived by fusion proteins, such as BCR-ABL, DEK-CAN, and ETV6-AML1 in different leukemias (45, 47, 48) , SYT-SSX in synovial sarcomas (44) , and PAX-FKHR in alveolar rhabdomyosarcomas (49) . In some instances, immunogenicity of these determinants has been shown in vivo based on a high frequency of antigen-specific T cells found in a fraction of patients (45, 48) . In addition, in a recent clinical trial in synovial sarcoma patients vaccinated with SYT-SSX -derived peptides, peptide-specific CTLs were induced in four of six patients and suppression of tumor progression was documented in one of six patients (51) .
Immunogenicity and immunodominance: frequent features of unique tumor antigens. One of the key questions, with respect to the antigenic repertoire of neoplastic cells, is which of the various classes of antigens thus far identified is the most relevant for tumor rejection and for the development of antigen-specific immunotherapy approaches. The coexpression of unique and shared antigenic determinants on neoplastic cells, which has been reported three decades ago, has offered the possibility to compare these two classes of determinants. In fact, early evidence obtained in the mid 1970s indicated that murine plasmacytomas and chemical carcinogen -induced fibrosarcomas expressed both unique and shared tumorassociated antigens (52 -54) . The finding that a single experimental tumor could express multiple tumor-associated antigens (TAA) of different classes (unique and shared) prompted investigations on the relative immunodominance of these determinants. The murine models investigated by Schreiber and colleagues in the early 1980s indicated that a single tumor could express multiple tumor-specific antigens and that there was a hierarchy of immunodominance among the epitopes. In fact, some of the TAA could be recognized only when the immunodominant epitopes had been lost through T cell -mediated immunoselection (55, 56) . By exploiting such approach of CTL-mediated immunoselection, on a chemically induced tumor, Dudley and Roopenian (57) showed that the same tumor expressed two unique and one shared epitope. However, the shared epitope was the weakest, and the response against such determinant could be revealed only in immunoselected variants lacking the two strong unique antigens. These initial studies provided also the earliest evidence for the shaping effect of the immune system on tumor immunogenicity, a concept that Dunn et al. (58) have later placed at the basis of the cancer immunoediting hypothesis.
In agreement with results initially obtained in experimental tumors, it soon became clear that even human tumors can coexpress both unique and shared determinants and that the immune repertoire of patients was not homogeneously distributed against the different classes of TAA. For example, the clonal analysis of the CTL-mediated response to human melanoma cells provided the evidence for coexpression of at least four classes of TAA on the same tumor (59, 60) . These classes included operationally-defined ''unique'' antigens. Such epitopes were defined by the reactivity of T cells that recognize only autologous tumor and not large arrays of allogeneic HLAmatched normal or neoplastic cells from different tissues. By a limiting dilution analysis designed to discriminate the recognition of melanoma cells and of normal HLA-matched melanocytes, we found that the HLA-A*0201 -restricted CD8 + immune repertoire to melanoma, in terms of precursor frequency, was mostly directed to antigens expressed on neoplastic cells and not on normal melanocytes (60). These results indicated not only coexpression of different classes of antigens on human melanoma cells but also immunodominance of the epitopes expressed only on the neoplastic cells over those shared with normal melanocytes (60) . Similarly, the analysis of HLA-A3 -restricted CTLs from a single patient indicated the simultaneous expression of both unique and shared TAA not found on HLA-matched melanocytes (61) . In agreement with these results, Lennerz et al. (20) have recently identified several new differentiation antigens and new gene mutations yielding at least five new unique antigens expressed by the neoplastic cells of a single melanoma patient. Interestingly, the T cell -mediated response from blood lymphocytes isolated over a 4-year interval from this patient showed that the response was dominated by T cells directed to the unique mutation-derived antigens (20) , suggesting immunodominance of such epitopes over the shared antigens expressed by the same tumor. It is, however, to be pointed out that an immune response to immunodominant epitopes is not necessarily associated with protective immunity. This is true not only in the antitumor response but it has been shown even in viral infections (62) .
A peculiar opportunity to compare unique and shared human tumor epitopes for immunogenicity and immunodominance has been offered by analysis of response to the idiotypic surface immunoglobulin expressed by B-cell malignancies. In this instance, the immunoglobulin heavy chain encodes both T cell -defined unique epitopes that derive from the hypervariable segments (63) and shared epitopes that derive from nonmutated, germ-line framework sequences (64) . In a recent study, Baskar et al. (65) looked at the fine specificity of the CD4 + and CD8 + T-cell response elicited in follicular lymphoma patients by vaccination with tumor-derived immunoglobulin conjugated to keyhole limpet hemocyanin and mixed with granulocyte macrophage colony-stimulating factor. The authors found that most of the vaccinated patients exhibited a vaccine-specific T-cell response. However, interestingly, such T-cell response was mainly directed to multiple epitopes within the hypervariable regions (CDR2 and CDR3) of the tumor immunoglobulin, and not to peptides derived from the framework regions of the same idiotypic protein (65) . In agreement with previous results obtained in experimental models (57) , this evidence suggests that unique, idiotypic epitopes of the tumor immunoglobulin are immunodominant over the shared determinants contained within the sequence of the same immunoglobulin. Moreover, these results suggest that the T-cell response to such unique antigens may contribute, together with anti-idiotypic humoral immunity (66) , to the clinical efficacy of idiotypic vaccination documented in B-cell tumor patients (39, 67) .
T-cell response to unique tumor antigens: evidence from regressing lesions and from long-term survivors. In vivo immune response to unique human tumor antigens has been documented in melanoma and lung cancer patients by looking at the presence, frequency, and function of antigen-specific T cells in regressing lesions or in long-term survivors. Clearly, this evidence does not necessarily mean that such immune response had a protective effect against tumor growth. However, the T-cell response to an immunogenic tumor antigen is expected to generate a high frequency of antigen-specific T cells and/or to yield differentiated T cells endowed with fast, secondary expansion in vitro on rechallenge with antigen. In agreement with these predictions, in a patient showing spontaneous regression of a primary melanoma, Zorn and Hercend (15) found a highly expanded TCRBV16 + T-cell population directed to a unique tumor antigen generated by a point mutation in a myosin gene. This finding suggests a role of the response to such unique determinant in the observed tumor regression. In another study, CD4 + T cells directed to a unique melanoma antigen generated by a mutant receptor-like tyrosine phosphatase n were found not only in a metastatic lesion but even in peripheral blood lymphocytes obtained almost 6 years later, when the patient was still disease-free (21) . Interestingly, T cells from peripheral blood lymphocytes and from tumor site showed antigen-specific IFN-g production in ELISPOT, without prior in vitro activation, consistent with previous priming in vivo and differentiation to effector stage (21) . Presence in peripheral blood of a high frequency of T cells directed to unique tumor antigens and/or rapid T-cell expansion in vitro on restimulation with antigen has been documented even in long-term survivors after surgery for lung cancer. Thus, in a disease-free lung cancer patient, by HLA tetramer analysis, antigen-specific T cells directed to a mutated malic enzyme have been found at frequencies of 0.1% to 0.4% of the CD8 + cells up to 10 years after initial surgery for squamous cell carcinoma (31) . In another patient, remaining disease-free after removal of a large-cell carcinoma of the lung, low-frequency T cells specific for a mutated a-actinin-4 gene, isolated 4 years later from peripheral blood, could readily be expanded in vitro on restimulation with antigen (30) . Interestingly, when a-actinin-4 -specific T cells from tumor site and peripheral blood were compared, the authors found that only the antigen-specific T cells with high functional avidity (i.e., T cells showing effective target lysis and/or cytokine secretion in response to low antigen doses) were expanded at tumor site whereas a low-avidity T-cell clone was expanded only in periphery (68) . Taken together, these studies provide strong evidence consistent with immunogenicity of unique tumor antigens expressed in human tumors and for selective expansion at tumor site of functional T cells directed to such epitopes. They also suggest that immune response to unique tumor antigens may even contribute to the favorable clinical evolution observed in the patients in whom such epitopes have been identified.
Immune selection: shared versus unique tumor antigens. Tumor escape mechanisms are a major hurdle for successful immunotherapy, and several studies support the evidence for the generation of antigen-loss variants in tumors subjected to the selective pressure of the immune response. Evidence consistent with such process has been frequently obtained in melanoma patients treated with immunotherapy targeting shared differentiation antigens. In an early study, in melanoma patients treated with immunogenic peptides from melanoma differentiation antigens gp100 or Melan-A/Mart-1 (+/À interleukin 2), Riker et al. (69) found an increase in the frequency of gp100-or Melan-A/Mart-1 negative lesions after therapy. In addition, pretherapy lesions with high expression of gp100 were more frequent in responding patients than in nonresponding ones (69) . These initial results suggested that vaccination against a class of nonmutated self-antigens can result in immunoselection in vivo, and that antigen expression in pretherapy neoplastic cells may be relevant in predicting the response to therapy. In a subsequent study in patients vaccinated against gp100, the same authors found that immunoselection occurred in responding lesions, without interfering with tumor regression, and did not occur in nonresponding lesions (70) . Appearance of antigen-loss variants has been described even after adoptive immunotherapy with Melan-A/Mart-1 and gp100-specific T-cell clones (71) . On the other hand, in a recent study, immunohistochemical analysis of antigen expression in recurrent tumors of melanoma patients vaccinated with a gp100 ''anchor-modified'' peptide did not provide conclusive evidence on the generation of antigen-loss variants, in spite of the generation of high levels of tumor antigen -specific T cells in all these patients (72) .
In contrast to the results obtained by looking at immune selection in the response to shared tumor antigens, different studies suggest that at least some unique tumor antigens may be resistant to immune selection in spite of their immunogenicity. Recently, in a melanoma patient in whom we identified a unique tumor antigen, recognized by HLA-A*0201 -restricted T cells, we had the opportunity to evaluate immunogenicity and retention in neoplastic cells of unique and shared TAA expressed by the same tumor (16) . The unique antigen was encoded by a mutated peroxiredoxin 5 (Prdx5) gene expressed in a tumor lacking the wild-type allele (16) . Because the patient expressed HLA-A2, we had the opportunity to compare the response against the unique antigen with that against a shared antigen (Melan-A/Mart-1 [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] ) recognized on the same tumor in the context of the same HLA restricting element. By HLA tetramer analysis, we found that mutant Prdx5-specific T cells were present in a tumor-invaded lymph node at a frequency similar to Melan-A/Mart-1 -specific T cells, but much higher than gp100-specific T cells (16) . Moreover, >50% of the T cells directed against Prdx5, or against Melan-A/Mart-1, showed a differentiated ''T Central memory '' or ''T Effector Memory '' phenotype consistent with previous priming and differentiation in vivo (16) . We also found that the mutant peroxiredoxin enzyme retained its antioxidant activity, protecting cells from oxidative stress (16) . Moreover, the mutated protein was expressed in all cells from a lymph node metastasis whereas expression of other shared antigens (Melan-A/Mart-1, tyrosinase, and gp100) showed strong intratumor heterogeneity (16) . These results suggest that unique tumor antigens that behave as mutant Prdx5 may, in principle, be considered as attractive targets for immunotherapy for at least two reasons: immunogenicity and ''resistance'' to loss of expression by immunoselection even in advanced cancers. Evidence consistent with resistance of at least some unique antigens to immunoselection has recently been described in patients vaccinated against the B-cell lymphoma idiotype (73) . In fact, in six mantle cell lymphoma patients treated with a B-cell idiotype -specific vaccine (73), administered after chemotherapy plus rituximab, the analysis of relapsing tumors indicated no mutations or change of expression of the surface immunoglobulin in spite of significant tumor-specific T-cell responses elicited in 87% of the 26 patients (73) . Although previous studies (74) had shown the emergence of idiotype-negative B-cell tumors, after immunotherapy with anti-idiotypic monoclonal antibodies, the more recent results (73) suggest that it is possible to boost in vivo the T-cell response to a unique tumor antigen without inducing antigen-loss variants of the tumor.
Evidence for immune recognition of unique tumor antigens in patients responding to immunotherapy. Immunogenicity, immunodominance, and evidence for resistance to immunoselection are attractive features of tumor antigens to be used as targets of immunotherapy approaches. The previously discussed evidence suggests that at least some unique tumor antigens may have such characteristics. On the other hand, the need for identifying the genes coding for such determinants in each patient has often hampered the development of clinical studies of immunotherapy aimed at boosting immunity to such class of epitopes. For this reason, and with the significant exception of idiotype vaccines in B-cell malignancies (39, 65 -67) , most immunotherapy studies thus far have targeted the class of shared tumor-associated antigens (75, 76) or have been designed to induce response to the whole array of determinants expressed by a tumor, without prior knowledge on the expression of unique determinants (77 -79) . In spite of these limitations, results from different clinical studies have indicated that patients subjected to active or adoptive immunotherapy (10, 18, 19, 80 -84) may develop responses to unique tumor antigens (Table 3) . Early clinical trials of adoptive T-cell transfer in melanoma patients indicated that significant clinical responses were associated with the infusion of T cells recognizing different antigens, including melanocyte lineage differentiation antigens, cancer testis antigens, and unique antigens (Table 3; refs. 10, 81 -84). More recently, remarkable clinical responses have been observed in patients who received adoptive transfer of tumor-reactive tumor-infiltrating lymphocytes and nonmyeloablative chemotherapy (85) . In these patients, a systematic approach to identify the tumor antigens recognized by the adoptively transferred T cells has indicated that unique tumor antigens are a relevant class of epitopes targeted by T cells that persist in vivo in responding patients (Table 3; refs. 18, 19, 80, 86, 87) . Even in tumors different from melanoma, response to unique antigens has been found to be associated with clinical response. In a metastatic renal cell carcinoma patient vaccinated with granulocyte macrophage colony-stimulating factor -transduced autologous tumor cells, and showing strong clinical response to the vaccine, Zhou et al. (35) found induction of a heterogeneous CD8 + T-cell repertoire directed not only to shared antigens but also to a new unique antigen encoded by a mutated integrator complex subunit 1 (KIAA1440) gene. Finally, current evidence indicates that even strategies involving active immunization with known melanocyte lineage differentiation antigens or cancer testis antigens can boost/prime response to previously unrecognized unique tumor antigens. Lurquin et al. (88) investigated the frequency of T cells in peripheral blood and tumor site of a melanoma patient vaccinated against a shared cancer testis antigen (MAGEA3). The results indicated that postvaccine lesions had a dramatic increase in frequency of T cells directed not to the MAGEA3 epitope but to other TAA. Interestingly, one of the Tcell clonotypes that were found at high frequency in postvaccine lesions, compared with prevaccine metastases or peripheral blood, was directed to a potential new unique antigen generated by mutation of a caseinolytic protease (88) . These latter results suggest that vaccination against shared tumor antigens may, at tumor site, provide conditions that favor activation of T cells directed to several different TAA, including unique TAA.
Strategies for the identification and targeting of unique tumor antigens in solid tumors. The general strategy for the identification of genes coding for tumor-associated antigens recognized by T cells depends on the availability of tumorspecific T-cell clones (see Fig. 1A for an outline of the strategy to identify unique tumor antigens defined by CD8 + T cells). In the instance of T cells that are thought to be directed to unique tumor antigens, T-cell clones are initially selected on the basis of reactivity only against the autologous tumor and not against panels of HLA-matched allogeneic tumors of the same histologic origin. The approach shown in Fig. 1A has been extensively used in the past to characterize most of the known unique tumor antigens described thus far (see Table 1 ) and is based on the expression, in appropriate recipient cells (such as COS cells), of cDNAs isolated from autologous tumor together with the HLA restricting element. This strategy has a significant limitation: only one antigen at a time can be identified. More recently, this approach has been modified and improved by Lennerz et al. (ref. 20; Fig. 1B ). The first change was the usage of polyclonal T-cell lines obtained by isolation of CD8 + T cells from short-term autologous mixed lymphocyte-tumor cell cultures (MLTC). The second modification of the cloning strategy was the introduction of an additional screening for recognition of COS cells transfected with known tumor antigens (to rule out recognition of previously identified antigens), as well as with each of the different HLA class I alleles of the patient (Fig. 1B) . In addition, the read-out system (based on cytokine production by T cells) was modified by introducing a quantitative assay (ELISPOT). On the basis of frequency of cytokine-producing T cells, such quantitative assay allows to discriminate distinct effectors, present even in the same polyclonal T-cell line and directed against different tumor-associated antigens (20) . By applying such technique, Lennerz et al. showed that it was possible to use polyclonal MLTC T-cell lines for the screening of COS transfectants, without prior knowledge of the relevant HLA restricting elements used by these effectors, among those expressed by the patient (20) . This strategy allowed the identification not only of three novel epitopes derived from melanoma differentiation antigens (tyrosinase and gp100) but also of five new unique antigens generated by somatic point mutations in different genes in the same melanoma patient (20) .
In spite of these technical improvements, in most patients with solid tumors, the identification of unique tumor antigens for immunotherapy purposes remains a difficult and Table 3 . Identification of antigens recognized by adoptively transferred T cells persisting in peripheral blood of clinically responding melanoma patients time-consuming task. Therefore, the available approaches for targeting unique tumor antigens in clinical studies of patientand tumor-specific immunotherapy are those based on adoptive cell transfer of ex vivo activated tumor-specific T cells (85, 89, 90) or on vaccines containing the whole repertoire of tumor antigens from the autologous tumor (77 -79) . Such vaccines in turn may express known shared tumor antigens as well as unknown unique epitopes. Several vaccines of this kind have been developed and novel approaches are being pursued including tumor-derived heat shock proteins, RNA to load antigen-presenting cells, or exosomes (91, 92) as a novel multiepitope antigen delivery system.
Conclusions
As reviewed recently by Rosenberg et al. (76) , the overall objective response rate seen in clinical studies of vaccination involving 1,306 patients with metastatic cancers was 3.3%. A large fraction of these studies have not been designed to target specifically unique tumor antigens but have attempted to promote/boost immune response to the shared determinants identified in several human tumors over the past 15 years. Several reasons can contribute to explain these disappointing results. These processes include tumor escape mechanisms, inefficient priming of CD4 + and CD8 + T cells, suppressive activity of regulatory T cells, inadequate T-cell differentiation to effector stage, and impaired homing of antigen-specific T cells to tumor site (93) . Such processes will likely hamper the efficacy of any vaccine targeting shared or unique tumor antigens. However, the previously discussed specific features often expressed by unique tumor antigens (such as immunogenicity, immunodominance, and resistance to immunoselection) might represent key factors for the efficacy of immune intervention strategies aimed at targeting this class of epitopes. + Tcells. A, the first step (1) requires the identification of aT-cell clone that recognizes in an HLA-restricted fashion only the autologous tumor and not panels of HLA-matched allogeneic tumors of the same histologic origin. mRNA isolated from the autologous tumor (2) is then used to generate a cDNA library (3) in appropriate expression vectors. Pools of plasmids from the library are then used to transfect COS cells together with an expression vector coding for the relevant HLA restricting element required by theT-cell clone (4). Such HLA restricting element can associate with peptides generated by the intracellular degradation of proteins resulting from the expression of the transfected cDNA segments (5). The COS transfectants are then cocultured with the specificT-cell clone (6) and T-cell recognition of an antigen-positive transfectant is verified by cytokine release assays (7). B, the previous strategy has been recently modified by Lennerz et al. (20) to allow the screening of COS cells transfected with each of the HLA class I alleles of the patient (8) and with pools of plasmids from the cDNA library generated from the autologous tumor. Such transfectants can be screened by a quantitative assay, such as the ELISPOT, for recognition by polyclonal short-term cell lines isolated by MLTC (9) . A distinct set of COS transfectants are generated that can express each of the known tumor-associated antigens expressed by the autologous tumor together with each of the HLA class I alleles of the patient.
